
Myostatin inhibitors will be bigger than any GLP-1 I just analyzed results from 4 recent Phase 2+ trials: + Bimagrumab (Lilly) + Trevogrumab & Garetosmab (Regeneron) + Apitegromab (Scholar Rock) + Enobosarm (Veru) The results are insane We're entering the Era of Enhancement:


















